Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | SAT1 | P21673 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL2776516 | 1.00 | S1PR2 (0.61) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL28194483 | 0.97 | S1PR2 (0.59) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL28584315 | 0.97 | S1PR2 (0.59) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL10877434 | 0.97 | S1PR2 (0.59) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL10873697 | 0.95 | S1PR2 (0.57) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL28992009 | 0.95 | S1PR2 (0.57) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL10873705 | 0.95 | S1PR2 (0.57) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL28726224 | 0.93 | S1PR2 (0.73) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Phosphoric Acid SCHEMBL9154480 | 0.93 | S1PR2 (0.73) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| Methyl Phosphonate SCHEMBL28374576 | 0.92 | S1PR2 (0.59) | S1PR2S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119793702-A | Method for separating and enriching chalcopyrite and enargite through floatation | 昆明理工大学 | 2025-04-11 | — | — | CN | claimed |
| CN-117363303-A | Reactive moisture-curing polyurethane hot melt adhesive with flame retardance and preparation method thereof | 重庆韩拓科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-119793702-B | Method for separating and enriching chalcopyrite and enargite through floatation | 昆明理工大学 | 2025-10-17 | — | — | CN | disclosed |
| CN-119793702-A | Method for separating and enriching chalcopyrite and enargite through floatation | 昆明理工大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-119793702-A | Method for separating and enriching chalcopyrite and enargite through floatation | 昆明理工大学 | 2025-04-11 | — | — | CN | disclosed |
| US-20250066848-A1 | DNA SEQUENCING BY SYNTHESIS USING MODIFIED NUCLEOTIDES AND NANOPORE DETECTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119463947-A | High-temperature-resistant lubricating oil and preparation method and application thereof | 广东嘉福新材料科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119463947-A | High-temperature-resistant lubricating oil and preparation method and application thereof | 广东嘉福新材料科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12173366-B2 | DNA sequencing by synthesis using modified nucleotides and nanopore detection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-24 | — | — | US | disclosed |
| CN-117363303-A | Reactive moisture-curing polyurethane hot melt adhesive with flame retardance and preparation method thereof | 重庆韩拓科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11795191-B2 | Method of preparation of nanopore and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-24 | — | — | US | disclosed |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
| EP-1723125-A1 | NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES | Auckland Uniservices Limited (NZ) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082867-A1 | NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-09-09 | — | — | WO | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| EP-0104888-A1 | Process for preparing 2-hydroxy-2-phenylethylamines | ELI LILLY AND COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795191-B2 | Method of preparation of nanopore and uses thereof | DNTT, NCL, PHAX | S1PR2 4102/4885S1PR1 4028/4885S1PR3 4280/4885 |
| US-20250066848-A1 | DNA SEQUENCING BY SYNTHESIS USING MODIFIED NUCLEOTIDES AND NANOPORE DETECTION | POLN, DNTT, NT5C3B | S1PR2 2725/4885S1PR1 2377/4885S1PR3 2914/4885 |
| US-12173366-B2 | DNA sequencing by synthesis using modified nucleotides and nanopore detection | POLN, DNTT, NT5C3B | S1PR2 2725/4885S1PR1 2377/4885S1PR3 2914/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | S1PR2 4031/4885S1PR1 3987/4885S1PR3 4242/4885 |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | HIF1AN, HIF1A, HYOU1 | S1PR2 1341/4885S1PR1 1236/4885S1PR3 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.